Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Shandong Jincheng Biopharmaceutical Co., Ltd., has received the CEP certificate for glutathione active pharmaceutical ingredient from the European Directorate for the Quality of Medicines (EDQM), enabling sales in the European market and enhancing competitiveness in the active pharmaceutical ingredient sector [1] Group 1 - Jincheng Biopharmaceutical has obtained the CEP certificate for glutathione, indicating compliance with European pharmacopoeia standards [1] - The CEP certificate will facilitate Jincheng Biopharmaceutical's expansion into overseas markets [1] - This achievement is expected to improve the company's competitiveness in the active pharmaceutical ingredient market [1]

证券之星消息，11月18日化学制药板块较上一交易日下跌0.75%，富祥药业领跌。当日上证指数报收于 3939.81，下跌0.81%。深证成指报收于13080.49，下跌0.92%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002020 | 京新药业 | 20.90 | 7.90% | 48.10万 | 10.02亿 | | 000566 | 因曲與 | 8.00 | 7.38% | 337.76万 | 26.98亿 | | 300086 | 康艺药业 | 11.81 | 6.30% | 146.60万 | 17.58亿 | | 002693 | *ST双成 | 8.46 | 4.96% | 27.04万 | 2.28亿 | | 301507 | 民生健康 | 17.61 | 4.14% | 40.27万 | 7.15亿 | | 688197 | 首药控股 | 41.69 | 2.71% | 1.40万 | 5819.19万 | | 301089 | 拓新药业 ...

Core Viewpoint - The company announced that its subsidiary, Tianyao Heping, has received registration certification from the Ministry of Health of the Republic of Panama for its injectable methylprednisolone sodium succinate (500mg freeze-dried powder injection), allowing for local production and sales [1] Group 1: Product Approval and Market Expansion - The approved drug is a corticosteroid used for anti-inflammatory treatments [1] - The registration application was submitted in 2024, and the certification was obtained in November 2025 [1] - The global sales figures for methylprednisolone injectable products are projected to be $526 million in 2023 and $521 million in 2024 [1] Group 2: Strategic Implications - This approval presents an opportunity for the company to expand its formulation business into the Panamanian market, enhancing its internationalization strategy [1] - However, there is uncertainty regarding the sales performance in this new market [1]

Market Overview - Major indices closed lower on Monday, with a trading volume of 1.93 trillion, a decrease of approximately 50 billion from the previous trading day[1] - The market showed a weak trend, with the Shanghai Composite Index down 0.46%, the Shenzhen Component down 0.11%, and the ChiNext Index down 0.2%[3] - Defensive sectors like banking, coal, and oil saw gains, while TMT sectors continued to adjust, indicating a lack of clear market direction[1] Industry Insights - Huawei is set to release breakthrough AI technology that could increase the utilization rate of computing resources from an industry average of 30%-40% to 70%[1] - The domestic water-saving industry market is estimated to exceed 760 billion, supported by the development of multiple water-saving industrial parks[9] Financial Data - From January to October, the national general public budget revenue reached 186,490 billion, a year-on-year increase of 0.8%[4] - The new fund issuance scale has surpassed 1 trillion this year, with a total of 1,377 new funds established, amounting to 995.977 billion[13]

Core Viewpoint - Hainan Haiyao's trading volume reached 2.245 billion RMB, marking the highest level since November 2, 2015, with a stock price increase of 10.07% and a turnover rate of 24.18% [2] Company Summary - Hainan Haiyao Co., Ltd. was established on December 30, 1992, with a registered capital of 1.297365126 billion RMB [2]

Core Viewpoint - Qianhong Biopharma's stock price has experienced fluctuations, with a year-to-date increase of 44.17%, but a recent decline in the last five trading days by 4.57% [1] Group 1: Company Overview - Qianhong Biopharma, established on April 30, 2003, and listed on February 18, 2011, is located in Changzhou, Jiangsu Province [2] - The company specializes in the research, production, and sales of various pharmaceutical products, including freeze-dried powders, injections, tablets, and raw materials [2] - The main revenue composition is 62.97% from formulations and 36.70% from raw materials [2] Group 2: Financial Performance - For the period from January to September 2025, Qianhong Biopharma achieved a revenue of 1.215 billion yuan, reflecting a year-on-year growth of 0.61%, and a net profit of 383 million yuan, up 23.79% year-on-year [2] - Cumulatively, the company has distributed 1.862 billion yuan in dividends since its A-share listing, with 453 million yuan distributed over the last three years [3] Group 3: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased to 73,600, with an average of 12,785 circulating shares per person, a decrease of 1.15% from the previous period [2] - The stock has appeared on the "Dragon and Tiger List" seven times this year, with the most recent instance on August 7, where it recorded a net purchase of 10.2288 million yuan [1]

Group 1: Industry Performance - The petrochemical index saw an overall increase, with six indices rising and only the chemical machinery index declining by 4.02% [1] - The chemical raw materials index rose by 3.44%, the pharmaceutical index increased by 3.09%, and the pesticide and fertilizer index went up by 3.18% [1] - In the oil sector, the oil processing index increased by 1.84%, the oil extraction index rose by 1.42%, and the oil trading index surged by 7.39% [1] Group 2: Commodity Prices - International crude oil prices experienced slight upward fluctuations, with WTI settling at $60.09 per barrel, up 0.57% from November 7, and Brent at $64.39 per barrel, up 1.19% [1] - The top five petrochemical products with the highest price increases included DMC (up 18.18%), natural rubber (up 13.22%), D4 (up 13.04%), 107 glue (up 12.71%), and methyl acrylate (up 8.03%) [1] - The five petrochemical products with the largest price declines were isooctyl acrylate (down 7.69%), 2,4-dichlorophenoxyacetic acid (down 4.29%), dichloromethane (down 3.64%), diethylene glycol (down 3.53%), and vitamin D3 (down 3.33%) [1] Group 3: Capital Market Performance - The top five listed chemical companies with the highest stock price increases were Shida Shenghua (up 43.44%), Yongtai Technology (up 33.89%), Aoke Shares (up 23.36%), Taihe Technology (up 23.59%), and Kaisheng New Materials (up 23.03%) [2] - The five listed chemical companies with the largest stock price declines included Xiangyuan New Materials (down 15.42%), Xinhang New Materials (down 14.15%), Dongcai Technology (down 13.52%), Kaili New Materials (down 12.60%), and Asia-Pacific Industry (down 11.16%) [2]

Core Viewpoint - The stock of XinNuoWei has experienced fluctuations, with a year-to-date increase of 24.73% but a significant decline of 35.29% over the past 60 days, indicating volatility in its market performance [1][2]. Company Overview - XinNuoWei, established on April 5, 2006, and listed on March 22, 2019, is based in Shijiazhuang, Hebei Province. The company focuses on the research, production, and sales of functional foods, with 88.93% of its revenue derived from functional foods and raw materials, 8.91% from biopharmaceuticals, and 2.16% from other sources [1][2]. Financial Performance - For the period from January to September 2025, XinNuoWei reported a revenue of 1.593 billion yuan, reflecting a year-on-year growth of 7.71%. However, the net profit attributable to the parent company was a loss of 24.0489 million yuan, a decrease of 117.26% compared to the previous year [2][3]. Shareholder Information - As of October 31, the number of shareholders for XinNuoWei increased by 32.87% to 21,800, with an average of 57,116 circulating shares per shareholder, down 24.74% from the previous period [2][3]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 17.7822 million shares, a decrease of 3.2169 million shares from the previous period [3]. Dividend Distribution - Since its A-share listing, XinNuoWei has distributed a total of 651 million yuan in dividends, with 500 million yuan distributed over the past three years [3].

Core Viewpoint - 博瑞医药's stock has experienced significant fluctuations in 2023, with a year-to-date increase of 73.80% but a recent decline in the last five trading days by 1.95% [2] Group 1: Stock Performance - As of November 18, 博瑞医药's stock price is 52.32 CNY per share, with a market capitalization of 22.137 billion CNY [1] - The stock has seen a 53.20% decline over the past 60 days [2] - The trading volume on November 18 was 1.17 billion CNY, with a turnover rate of 0.52% [1] Group 2: Financial Performance - For the period from January to September 2025, 博瑞医药 reported a revenue of 874 million CNY, a year-on-year decrease of 10.50% [2] - The net profit attributable to shareholders for the same period was 50.32 million CNY, down 71.64% year-on-year [2] Group 3: Shareholder Information - As of September 30, 2025, 博瑞医药 had 19,600 shareholders, an increase of 104.44% from the previous period [2] - The average number of circulating shares per shareholder decreased by 51.05% to 21,629 shares [2] - The company has distributed a total of 246 million CNY in dividends since its A-share listing, with 129 million CNY distributed in the last three years [3] Group 4: Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the fifth-largest circulating shareholder, holding 8.7219 million shares, an increase of 5.471 million shares from the previous period [3] - The ninth-largest circulating shareholder is Innovation Drug, holding 2.9109 million shares, with an increase of 98,300 shares from the previous period [3]

Core Viewpoint - Haisun Pharmaceutical's stock has experienced significant growth this year, with a year-to-date increase of 237.69%, and recent trading activity shows continued interest from institutional investors [2][3]. Group 1: Stock Performance - As of November 18, Haisun Pharmaceutical's stock price was 67.74 CNY per share, with a market capitalization of 8.129 billion CNY [1]. - The stock has seen a rise of 18.68% over the past five trading days, 19.34% over the past 20 days, and 14.81% over the past 60 days [2]. - The company has appeared on the "Dragon and Tiger List" eight times this year, with the most recent net buy of 62.603 million CNY on November 14 [2]. Group 2: Financial Performance - For the period from January to September 2025, Haisun Pharmaceutical reported revenue of 472 million CNY, reflecting a year-on-year growth of 30.80%, and a net profit attributable to shareholders of 32.6785 million CNY, up 16.22% year-on-year [3]. - Cumulative cash dividends since the company's A-share listing amount to 161 million CNY, with 18 million CNY distributed over the past three years [4]. Group 3: Shareholder Structure - As of November 10, the number of shareholders for Haisun Pharmaceutical was 22,100, a decrease of 2.84% from the previous period, with an average of 3,709 circulating shares per shareholder, an increase of 2.93% [3]. - New institutional shareholders include several funds, such as China Europe Enjoy Life Mixed A and Huashan Pharmaceutical Biological Stock Initiation A, indicating growing institutional interest [4]. Group 4: Business Overview - Haisun Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, specializes in the research, production, and sales of chemical preparations, raw materials, and intermediates [2]. - The company's main revenue sources include cardiovascular drugs (87.12%), antibiotics (5.69%), and other therapeutic categories [2].